mortality/aging
• loss of Dok2 shortened lifespan to about 283 days from about 321 days in mice that are hemizygous for Tg(BCR/ABL1)5Hhi and wild-type for Dok2
|
neoplasm
• inactivation of Dok2 accelerated the onset of the chronic phase and the fatal blastic phase
• acceleration was not as severe as in homozygous null mice
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
chronic myeloid leukemia | DOID:8552 |
OMIM:608232 |
J:95334 |